Published in Int Immunol on May 06, 2011
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PLoS One (2013) 1.06
Increased expression of bHLH transcription factor E2A (TCF3) in prostate cancer promotes proliferation and confers resistance to doxorubicin induced apoptosis. Biochem Biophys Res Commun (2012) 1.00
ID helix-loop-helix proteins as determinants of cell survival in B-cell chronic lymphocytic leukemia cells in vitro. Mol Cancer (2015) 0.84
E2A predicts prognosis of colorectal cancer patients and regulates cancer cell growth by targeting miR-320a. PLoS One (2014) 0.76
Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms? Immunology (2014) 0.76
Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia. Tumour Biol (2016) 0.75
Epigenetic and genetic alterations and their influence on gene regulation in chronic lymphocytic leukemia. BMC Genomics (2017) 0.75
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Chronic lymphocytic leukemia. N Engl J Med (2005) 9.99
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med (2001) 5.66
E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell (1994) 5.41
The helix-loop-helix gene E2A is required for B cell formation. Cell (1994) 4.59
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood (2008) 3.85
E-proteins directly regulate expression of activation-induced deaminase in mature B cells. Nat Immunol (2003) 3.03
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood (2008) 2.94
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood (2008) 2.88
Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol (1997) 2.71
Flow cytometric immunophenotyping for hematologic neoplasms. Blood (2008) 2.40
Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol (2005) 2.31
Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity (2008) 2.11
Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J Immunol (2008) 1.94
B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood (2002) 1.94
E2A activity is induced during B-cell activation to promote immunoglobulin class switch recombination. EMBO J (1999) 1.93
Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res (2006) 1.89
Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood (2010) 1.79
BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood (2008) 1.78
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol (2010) 1.77
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood (2007) 1.69
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood (2008) 1.67
Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol (2009) 1.64
Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest (2003) 1.63
Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood (2001) 1.55
E47 controls the developmental integrity and cell cycle quiescence of multipotential hematopoietic progenitors. J Immunol (2008) 1.51
E47 is required for V(D)J recombinase activity in common lymphoid progenitors. J Exp Med (2005) 1.44
Receptor editing and marginal zone B cell development are regulated by the helix-loop-helix protein, E2A. J Exp Med (2004) 1.42
Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia (2010) 1.35
Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol (2006) 1.32
Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol (2006) 1.24
Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev (2008) 1.18
Decreased E12 and/or E47 transcription factor activity in the bone marrow as well as in the spleen of aged mice. J Immunol (2003) 1.13
Reduced Ig class switch in aged mice correlates with decreased E47 and activation-induced cytidine deaminase. J Immunol (2004) 1.11
New prognostic markers in chronic lymphocytic leukemia. Blood Rev (2008) 1.11
Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol (2010) 1.07
Id3 induces growth arrest and caspase-2-dependent apoptosis in B lymphocyte progenitors. J Immunol (2005) 1.06
Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood (1998) 1.04
Autocrine role for interleukin-8 in Bartonella henselae-induced angiogenesis. Infect Immun (2006) 1.03
Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia (2007) 1.02
Molecular resolution of the B cell landscape. Curr Opin Immunol (2011) 0.93
Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist (2006) 0.93
A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res (2009) 0.93
Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. Leuk Lymphoma (1996) 0.92
E47 regulates hematopoietic stem cell proliferation and energetics but not myeloid lineage restriction. Blood (2011) 0.92
Gene expression profiling of E2F-1-induced apoptosis. Gene (2004) 0.87
B-cell receptor activation inhibits AID expression through calmodulin inhibition of E-proteins. Proc Natl Acad Sci U S A (2008) 0.86
Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk (2010) 0.81
Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases. Leukemia (2003) 0.81
Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours. Clin Endocrinol (Oxf) (2007) 0.80
Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. Exp Hematol (2003) 0.79
Initiation of antigen receptor-dependent differentiation into plasma cells by calmodulin inhibition of E2A. J Immunol (2009) 0.77
International network of cancer genome projects. Nature (2010) 20.35
Sequencing of 50 human exomes reveals adaptation to high altitude. Science (2010) 11.27
The influence of age on T cell generation and TCR diversity. J Immunol (2005) 4.36
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Three genomes from the phylum Acidobacteria provide insight into the lifestyles of these microorganisms in soils. Appl Environ Microbiol (2009) 2.75
The comprehensive microbial resource. Nucleic Acids Res (2009) 2.46
Flow cytometric immunophenotyping for hematologic neoplasms. Blood (2008) 2.40
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol (2004) 2.37
A critical role for TCF-1 in T-lineage specification and differentiation. Nature (2011) 2.15
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood (2014) 2.01
Downstream sequence elements with different affinities for the hnRNP H/H' protein influence the processing efficiency of mammalian polyadenylation signals. Nucleic Acids Res (2002) 2.00
Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum (2005) 1.88
Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol (2010) 1.81
Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol (2011) 1.76
Erythroid/myeloid progenitors and hematopoietic stem cells originate from distinct populations of endothelial cells. Cell Stem Cell (2011) 1.76
Elevated levels of the 64-kDa cleavage stimulatory factor (CstF-64) in lipopolysaccharide-stimulated macrophages influence gene expression and induce alternative poly(A) site selection. J Biol Chem (2005) 1.74
Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther (2008) 1.73
The hnRNPs F and H2 bind to similar sequences to influence gene expression. Biochem J (2006) 1.62
Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants. PLoS One (2008) 1.59
E47 controls the developmental integrity and cell cycle quiescence of multipotential hematopoietic progenitors. J Immunol (2008) 1.51
Carbon dioxide postcombustion capture: a novel screening study of the carbon dioxide absorption performance of 76 amines. Environ Sci Technol (2009) 1.46
IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood (2011) 1.43
Transcription elongation factor ELL2 directs immunoglobulin secretion in plasma cells by stimulating altered RNA processing. Nat Immunol (2009) 1.43
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma. Leuk Lymphoma (2014) 1.40
Comparison of the sensitivity and specificity of 5 image sets of dual-energy computed tomography for detecting first-pass myocardial perfusion defects compared with positron emission tomography. Medicine (Baltimore) (2014) 1.38
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res (2009) 1.37
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders. J Med Chem (2008) 1.35
Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate (2006) 1.32
Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol (2006) 1.30
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol (2007) 1.28
Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun (2007) 1.27
A comprehensive survey of miRNA repertoire and 3' addition events in the placentas of patients with pre-eclampsia from high-throughput sequencing. PLoS One (2011) 1.26
Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate (2009) 1.26
Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci (2007) 1.25
Recent advances of IMiDs in cancer therapy. Curr Opin Oncol (2010) 1.25
Comparative genomic evidence for a close relationship between the dimorphic prosthecate bacteria Hyphomonas neptunium and Caulobacter crescentus. J Bacteriol (2006) 1.23
N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res (2008) 1.22
Induction of CD56 and TCR-independent activation of T cells with aging. J Immunol (2008) 1.22
Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol (2011) 1.21
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol (2008) 1.21
CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood (2002) 1.21
Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest (2011) 1.19
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol (2013) 1.19
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol (2013) 1.17
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood (2006) 1.17
Contrast-enhanced whole-heart coronary MRA at 3.0T for the evaluation of cardiac venous anatomy. Int J Cardiovasc Imaging (2010) 1.17
The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling. Sci Signal (2013) 1.16
Resistance to age-dependent thymic atrophy in long-lived mice that are deficient in pregnancy-associated plasma protein A. Proc Natl Acad Sci U S A (2009) 1.15
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood (2002) 1.15
An evolutionarily conserved autoinhibitory molecular switch in ELMO proteins regulates Rac signaling. Curr Biol (2010) 1.15
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res (2006) 1.14
Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum (2007) 1.14
C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood (2009) 1.14
Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res (2008) 1.13
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood (2005) 1.13
Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum (2009) 1.13
The role of microRNA in human lung squamous cell carcinoma. Cancer Genet Cytogenet (2010) 1.13
Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest (2011) 1.10
Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum (2004) 1.08
Distinct transcriptional control mechanisms of killer immunoglobulin-like receptors in natural killer (NK) and in T cells. J Biol Chem (2005) 1.07
Automated segmentation of outer retinal layers in macular OCT images of patients with retinitis pigmentosa. Biomed Opt Express (2011) 1.07
Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood (2004) 1.07
Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol (2008) 1.07
64-MDCT coronary angiography: phantom study of effects of vascular attenuation on detection of coronary stenosis. AJR Am J Roentgenol (2008) 1.07
Total concentrations and speciation of heavy metals in municipal sludge from Changsha, Zhuzhou and Xiangtan in middle-south region of China. J Hazard Mater (2008) 1.06
Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol (2008) 1.06
Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol (2008) 1.04
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res (2002) 1.04
Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J Transl Med (2013) 1.04
The anaphase-promoting complex coordinates initiation of lens differentiation. Mol Biol Cell (2007) 1.03
IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol (2008) 1.01
A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest (2010) 1.00
Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background. PLoS One (2012) 1.00
An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. J Neurosci (2013) 1.00
CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis. Arthritis Rheum (2007) 1.00
Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther (2008) 1.00
Production of raw cassava starch-degrading enzyme by Penicillium and its use in conversion of raw cassava flour to ethanol. J Ind Microbiol Biotechnol (2010) 0.99
PCR Mutagenesis by Overlap Extension and Gene SOE. CSH Protoc (2008) 0.98
Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol (2013) 0.98
G-protein-coupled receptor 30 mediates rapid neuroprotective effects of estrogen via depression of NR2B-containing NMDA receptors. J Neurosci (2012) 0.98
Hematopoiesis sculpted by pathogens: Toll-like receptors and inflammatory mediators directly activate stem cells. Cytokine (2011) 0.98
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood (2009) 0.97
Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood (2012) 0.97
Innate versus adaptive immunity: a paradigm past its prime? Cancer Res (2007) 0.96
MACC1 is related to colorectal cancer initiation and early-stage invasive growth. Am J Clin Pathol (2013) 0.95
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol Cancer Ther (2008) 0.95
miR-302b is a potential molecular marker of esophageal squamous cell carcinoma and functions as a tumor suppressor by targeting ErbB4. J Exp Clin Cancer Res (2014) 0.95
Anti-idiotype antibody vaccine therapy for cancer. Expert Opin Biol Ther (2002) 0.95
Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother (2009) 0.95
Proteolysis of CDH1 enhances susceptibility to UV radiation-induced apoptosis. Carcinogenesis (2008) 0.95
Diversity of NKR expression in aging T cells and in T cells of the aged: the new frontier into the exploration of protective immunity in the elderly. Exp Gerontol (2005) 0.95